专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130172317A1 TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION HAVING AN ANALGESIC ACTIVITY COMPRISING THE SAME 有权
标题翻译：具有包括其同源活性的TRIAZINE衍生物和药物组合物
公开(公告)号：US20130172317A1
公开(公告)日：2013-07-04
申请号：US13814346
申请日：2011-08-09
申请人： Hiroyuki Kai , Takayuki Kameyama , Tohru Horiguchi , Kentaro Asahi , Takeshi Endoh , Yasuhiko Fujii , Takuya Shintani , Ken'ichiroh Nakamura , Sae Jikihara , Tsuyoshi Hasegawa , Miho Oohara , Yukio Tada , Toshikatsu Maki , Akira Iida
发明人： Hiroyuki Kai , Takayuki Kameyama , Tohru Horiguchi , Kentaro Asahi , Takeshi Endoh , Yasuhiko Fujii , Takuya Shintani , Ken'ichiroh Nakamura , Sae Jikihara , Tsuyoshi Hasegawa , Miho Oohara , Yukio Tada , Toshikatsu Maki , Akira Iida
IPC分类号： C07D251/46 , C07D417/12 , C07D413/12 , C07D405/06 , C07D401/14 , C07D251/52 , C07D405/14 , C07D401/12 , C07D403/12 , C07D403/04 , C07D413/14
CPC分类号： C07D251/46 , C07D251/52 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/06 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14
摘要： The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect.A pharmaceutical composition having an analgesic effect or an improving effect of urination disorder comprising a compound of the formula (I): wherein Rh and Rj are taken together to form a bond; Ra and Rb and/or Rd and Re are taken together to form oxo or the like; Rc is hydrogen, substituted or unsubstituted alkyl or the like; Rf is —(CR4aR4b)n—R2; R4a and R4b are hydrogen, substituted or unsubstituted alkyl or the like; R2 is substituted or unsubstituted cycloalkyl or the like; n is an integer of 1 to 4; —Rg is —X—R3; —X— is —O—, —S— or the like; R3 is substituted or unsubstituted cycloalkyl or the like, or its pharmaceutically acceptable salt or a solvate thereof.
摘要翻译：本发明提供具有P2X3和/或P2X2 / 3受体拮抗作用的新化合物。一种具有止痛作用或排尿障碍改善作用的药物组合物，其包含式（I）化合物：其中Rh和Rj一起形成键; Ra和Rb和/或Rd和Re一起形成氧代等; Rc是氢，取代或未取代的烷基等; Rf是 - （CR4aR4b）n-R2; R4a和R4b是氢，取代或未取代的烷基等; R2是取代或未取代的环烷基等; n为1〜4的整数， -Rg为-X-R3; -X-是-O-，-S-等; R3是取代或未取代的环烷基等，或其药学上可接受的盐或溶剂合物。

2. 发明授权

US09150546B2 Triazine derivative and pharmaceutical composition comprising the same 有权
标题翻译：三嗪衍生物及其组合物
公开(公告)号：US09150546B2
公开(公告)日：2015-10-06
申请号：US13201209
申请日：2010-02-10
申请人： Hiroyuki Kai , Takayuki Kameyama , Tsuyoshi Hasegawa , Miho Oohara , Yukio Tada , Takeshi Endoh
发明人： Hiroyuki Kai , Takayuki Kameyama , Tsuyoshi Hasegawa , Miho Oohara , Yukio Tada , Takeshi Endoh
IPC分类号： A61K31/535 , A61K31/53 , C07D403/06 , C07D251/46 , C07D251/52 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/06 , C07D405/12 , C07D409/06 , C07D413/12
CPC分类号： C07D251/46 , C07D251/16 , C07D251/44 , C07D251/52 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/06 , C07D405/12 , C07D409/06 , C07D413/12
摘要： The present invention provides a novel P2X3 and/or P2X2/3 receptor antagonist.A compound represented by the formula (I): wherein Ra, Rb and Rc are, (a) Ra and Rb are taken together ═Z; and Rc is a group represented by R1c; or (b) Rb and Rc are taken together to form a bond; and Ra is a group represented by —Y—R1a; R1a and R1c are each independently hydrogen, substituted or unsubstituted alkyl, etc.; R2 and R3 are each independently substituted or unsubstituted aryl, etc.; R4a and R4b are each independently hydrogen, substituted or unsubstituted alkyl, etc.; X is —N(R5)—, etc.; R5 is hydrogen, substituted or unsubstituted lower alkyl, etc.; —Y— is —O—, etc.; ═Z is ═O, etc.; and n is an integer of 0 to 4.
摘要翻译：本发明提供了一种新型的P2X3和/或P2X2 / 3受体拮抗剂。由式（I）表示的化合物：其中Ra，Rb和Rc为（a）Ra和Rb一起为= Z; Rc为由R1c表示的基团; 或（b）Rb和Rc一起形成键; 并且R a是由-Y-R 1a表示的基团; R1a和R1c各自独立地为氢，取代或未取代的烷基等; R2和R3各自独立地是取代或未取代的芳基等; R4a和R4b各自独立地为氢，取代或未取代的烷基等; X是-N（R 5） - 等; R5是氢，取代或未取代的低级烷基等; -Y-是-O-等; ═Z是═O等; n为0〜4的整数。

3. 发明申请

US20110319414A1 NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 有权
标题翻译：新型TRIAZINE衍生物和药物组合物
公开(公告)号：US20110319414A1
公开(公告)日：2011-12-29
申请号：US13201209
申请日：2010-02-10
申请人： Hiroyuki Kai , Takayuki Kameyama , Tsuyoshi Hasegawa , MIho Oohara , Yukio Tada , Takeshi Endoh
发明人： Hiroyuki Kai , Takayuki Kameyama , Tsuyoshi Hasegawa , MIho Oohara , Yukio Tada , Takeshi Endoh
IPC分类号： A61K31/53 , C07D251/46 , C07D403/06 , A61P7/00 , C07D413/12 , A61K31/5377 , A61P29/00 , A61P25/00 , C07D251/38 , C07D251/52
CPC分类号： C07D251/46 , C07D251/16 , C07D251/44 , C07D251/52 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/06 , C07D405/12 , C07D409/06 , C07D413/12
摘要： The present invention provides a novel P2X3 and/or P2X2/3 receptor antagonist.A compound represented by the formula (I); wherein Ra, Rb and Rc are, (a) Ra and Rb are taken together ═Z; and Rc is a group represented by R1c; or (b) Rb and Rc are taken together to form a bond; and Ra is a group represented by —Y—R1a; R1a and R1c are each independently hydrogen, substituted or unsubstituted alkyl, etc.; R2 and R3 are each independently substituted or unsubstituted aryl, etc.; R4a and R4b are each independently hydrogen, substituted or unsubstituted alkyl, etc.; X is —N(R5)—, etc.; R5 is hydrogen, substituted or unsubstituted lower alkyl, etc.; —Y— is —O—, etc.; ═Z is ═O, etc.; and n is an integer of 0 to 4.
摘要翻译：本发明提供了一种新型的P2X3和/或P2X2 / 3受体拮抗剂。由式（I）表示的化合物; 其中Ra，Rb和Rc为（a）Ra和Rb一起为= Z; Rc为由R1c表示的基团; 或（b）Rb和Rc一起形成键; 并且R a是由-Y-R 1a表示的基团; R1a和R1c各自独立地为氢，取代或未取代的烷基等; R2和R3各自独立地是取代或未取代的芳基等; R4a和R4b各自独立地为氢，取代或未取代的烷基等; X是-N（R 5） - 等; R5是氢，取代或未取代的低级烷基等; -Y-是-O-等; ═Z是═O等; n为0〜4的整数。

4. 发明申请

US20130225596A1 NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) 有权
标题翻译：新型杂环衍生物和药物组合物（如修饰）
公开(公告)号：US20130225596A1
公开(公告)日：2013-08-29
申请号：US13816085
申请日：2011-08-09
申请人： Hiroyuki Kai , Takeshi Endoh , Sae Jikihara , Kentaro Asahi , Tohru Horiguchi
发明人： Hiroyuki Kai , Takeshi Endoh , Sae Jikihara , Kentaro Asahi , Tohru Horiguchi
IPC分类号： C07C233/75 , C07D239/84 , C07D213/74 , C07C217/84 , C07D211/72 , C07D405/06 , C07C217/80 , C07D413/12 , C07D409/12 , C07D409/06 , C07D277/28 , C07D401/14 , C07D237/04
CPC分类号： C07D239/545 , C07C217/80 , C07C217/84 , C07C217/92 , C07C233/25 , C07C233/75 , C07C2601/14 , C07D211/72 , C07D213/64 , C07D213/69 , C07D213/74 , C07D213/79 , C07D213/80 , C07D213/82 , C07D215/22 , C07D215/56 , C07D217/22 , C07D217/24 , C07D231/38 , C07D233/88 , C07D233/96 , C07D235/30 , C07D237/04 , C07D237/20 , C07D237/32 , C07D239/42 , C07D239/47 , C07D239/48 , C07D239/54 , C07D239/557 , C07D239/78 , C07D239/84 , C07D239/95 , C07D239/96 , C07D241/20 , C07D255/02 , C07D261/12 , C07D263/32 , C07D263/34 , C07D263/48 , C07D265/06 , C07D265/10 , C07D265/26 , C07D265/36 , C07D277/20 , C07D277/28 , C07D277/34 , C07D277/38 , C07D277/42 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/06 , C07D409/06 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14
摘要： The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect.A pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic effect comprising a compound of the formula (I): wherein ring A is substituted or unsubstituted 5 to 7-membered cycloalkane, substituted or unsubstituted 5 to 7-membered cycloalkene or the like; C is a carbon atom; —X— is —N(R16)— or the like; R16 is hydrogen, substituted or unsubstituted alkyl or the like; R7 is substituted or unsubstituted 5- or 6-membered heteroaryl, substituted or unsubstituted 6 to 10 membered aryl; Q1 and Q2 are each independently a carbon atom or a nitrogen atom; -L- is —O—, —S— or the like; R6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl or the like; R2 is hydrogen, hydroxy or the like, or its pharmaceutically acceptable salt or a solvate thereof.
摘要翻译：本发明提供具有P2X3和/或P2X2 / 3受体拮抗作用的新化合物。一种具有P2X3和/或P2X2 / 3受体拮抗作用的药物组合物，其包含式（I）化合物：其中环A是取代或未取代的5至7元环烷烃，取代或未取代的5至7元环烯烃或喜欢; C是碳原子; -X-是-N（R 16） - 等; R 16是氢，取代或未取代的烷基等; R 7是取代或未取代的5元或6元杂芳基，取代或未取代的6至10元芳基; Q1和Q2各自独立地为碳原子或氮原子; -L-是-O-，-S-等; R6是取代或未取代的环烷基，取代或未取代的环烯基等; R2是氢，羟基等，或其药学上可接受的盐或其溶剂合物。

5. 发明授权

US09212130B2 Heterocyclic derivative and pharmaceutical composition comprising the same 有权
标题翻译：杂环衍生物和包含其的药物组合物
公开(公告)号：US09212130B2
公开(公告)日：2015-12-15
申请号：US13816085
申请日：2011-08-09
申请人： Hiroyuki Kai , Takeshi Endoh , Sae Jikihara , Tohru Horiguchi
发明人： Hiroyuki Kai , Takeshi Endoh , Sae Jikihara , Tohru Horiguchi
IPC分类号： A61K31/505 , A61K31/497 , A61K31/44 , A61K31/135 , A61K31/425 , C07C233/75 , C07C217/84 , C07C217/80 , C07D401/14 , C07D239/84 , C07D211/72 , C07D237/04 , C07C217/92 , C07D213/74 , C07D213/80 , C07D213/82 , C07D215/22 , C07D217/24 , C07D231/38 , C07D233/96 , C07D235/30 , C07D237/32 , C07D239/42 , C07D239/47 , C07D239/54 , C07D239/95 , C07D239/96 , C07D241/20 , C07D255/02 , C07D261/12 , C07D263/32 , C07D263/34 , C07D263/48 , C07D265/10 , C07D265/26 , C07D265/36 , C07D277/20 , C07D277/34 , C07D277/38 , C07D401/12 , C07D405/12 , C07D405/14 , C07D417/12 , C07D417/14 , C07D277/28 , C07D405/06 , C07D409/06 , C07D409/12 , C07D413/12 , C07D407/06 , C07C233/25 , C07D215/56 , C07D217/22 , C07D233/88 , C07D237/20 , C07D239/48 , C07D239/545 , C07D239/557 , C07D239/78 , C07D265/06 , C07D277/42 , C07D213/69
CPC分类号： C07D239/545 , C07C217/80 , C07C217/84 , C07C217/92 , C07C233/25 , C07C233/75 , C07C2601/14 , C07D211/72 , C07D213/64 , C07D213/69 , C07D213/74 , C07D213/79 , C07D213/80 , C07D213/82 , C07D215/22 , C07D215/56 , C07D217/22 , C07D217/24 , C07D231/38 , C07D233/88 , C07D233/96 , C07D235/30 , C07D237/04 , C07D237/20 , C07D237/32 , C07D239/42 , C07D239/47 , C07D239/48 , C07D239/54 , C07D239/557 , C07D239/78 , C07D239/84 , C07D239/95 , C07D239/96 , C07D241/20 , C07D255/02 , C07D261/12 , C07D263/32 , C07D263/34 , C07D263/48 , C07D265/06 , C07D265/10 , C07D265/26 , C07D265/36 , C07D277/20 , C07D277/28 , C07D277/34 , C07D277/38 , C07D277/42 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/06 , C07D409/06 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14
摘要： The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect.A pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic effect comprising a compound of the formula (I): wherein ring A is substituted or unsubstituted 5 to 7-membered cycloalkane, substituted or unsubstituted 5 to 7-membered cycloalkene or the like; C is a carbon atom; —X— is —N(R16)— or the like; R16 is hydrogen, substituted or unsubstituted alkyl or the like; R7 is substituted or unsubstituted 5- or 6-membered heteroaryl, substituted or unsubstituted 6 to 10 membered aryl; Q1 and Q2 are each independently a carbon atom or a nitrogen atom; -L- is —O—, —S— or the like; R6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl or the like; R2 is hydrogen, hydroxy or the like, or its pharmaceutically acceptable salt or a solvate thereof.
摘要翻译：本发明提供具有P2X3和/或P2X2 / 3受体拮抗作用的新化合物。一种具有P2X3和/或P2X2 / 3受体拮抗作用的药物组合物，其包含式（I）化合物：其中环A是取代或未取代的5至7元环烷烃，取代或未取代的5至7元环烯烃或喜欢; C是碳原子; -X-是-N（R 16） - 等; R 16是氢，取代或未取代的烷基等; R 7是取代或未取代的5元或6元杂芳基，取代或未取代的6至10元芳基; Q1和Q2各自独立地为碳原子或氮原子; -L-是-O-，-S-等; R6是取代或未取代的环烷基，取代或未取代的环烯基等; R2是氢，羟基等，或其药学上可接受的盐或其溶剂合物。

6. 发明申请

US20110183939A1 NOVEL PYROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 失效
标题翻译：新颖的吡咯烷酮衍生物和药物组合物
公开(公告)号：US20110183939A1
公开(公告)日：2011-07-28
申请号：US13121072
申请日：2009-09-24
申请人： Hiroyuki Kai , Yoshiyuki Taoda , Takeshi Endoh , Tohru Horiguchi , Kentaro Asahi , Hiroyuki Tobinaga
发明人： Hiroyuki Kai , Yoshiyuki Taoda , Takeshi Endoh , Tohru Horiguchi , Kentaro Asahi , Hiroyuki Tobinaga
IPC分类号： A61K31/695 , A61K31/4439 , C07D487/04 , A61K31/422 , A61K31/4162 , A61K31/444 , C07F7/02 , A61K31/4245 , C07D413/14 , A61K31/5377
CPC分类号： C07D487/04 , C07D207/38 , C07D401/04 , C07D401/10 , C07D403/04 , C07D405/14 , C07D409/10 , C07D409/14 , C07D413/10 , C07D413/14 , C07D417/04
摘要： The present invention provides a novel P2X3 and/or P2X2/3 receptor antagonist.A compound represented by the formula (I); wherein Z1 is optionally protected hydroxy, etc.; Z2 is —C(═O)—, etc.; Z3a and Z3b are taken together ═O or ═S; t is an integer of 0 to 4; R4a and R4b are each independently, hydrogen or substituted or unsubstituted lower alkyl, etc.; m and n are each independently an integer of 0 to 2; k is an integer of 0 or 1; Ring A is an aromatic carbocyclic ring or a heterocyclic ring, etc.; B is aromatic carbocyclic ring-diyl or heterocyclic ring-diyl, etc.; R1a and R1b are each independently halogen, hydroxy, substituted or unsubstituted lower alkyl, etc.; R2 is substituted or unsubstituted alkyl, etc.; R3 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, etc.; or its pharmaceutically acceptable salt, or a solvate thereof is provided.
摘要翻译：本发明提供了一种新型的P2X3和/或P2X2 / 3受体拮抗剂。由式（I）表示的化合物; 其中Z1是任选保护的羟基等; Z2是-C（= O） - 等; Z3a和Z3b合在一起= = 0或= t为0〜4的整数; R4a和R4b各自独立地为氢或取代或未取代的低级烷基等; m和n各自独立地为0〜2的整数。 k是0或1的整数; 环A是芳族碳环或杂环等; B是芳族碳环环 - 二基或杂环环二基等; R1a和R1b各自独立地为卤素，羟基，取代或未取代的低级烷基等; R2是取代或未取代的烷基等; R3是取代或未取代的烷基，取代或未取代的芳基或取代或未取代的杂环基等; 或其药学上可接受的盐或其溶剂合物。

7. 发明授权

US08575197B2 Pyrolinone derivative and pharmaceutical composition comprising the same 失效
标题翻译：吡罗啉酮衍生物及其组合物
公开(公告)号：US08575197B2
公开(公告)日：2013-11-05
申请号：US13121072
申请日：2009-09-24
申请人： Hiroyuki Kai , Yoshiyuki Taoda , Takeshi Endoh , Kentaro Asahi , Hiroyuki Tobinaga
发明人： Hiroyuki Kai , Yoshiyuki Taoda , Takeshi Endoh , Kentaro Asahi , Hiroyuki Tobinaga
IPC分类号： A61K31/4418 , A61K31/443 , A61K31/4439 , A61K31/422 , A61K31/4245 , A61K31/402 , A61K31/4025 , C07D207/38 , C07D271/06 , C07D261/08 , C07D409/10 , C07D403/14 , C07D413/14 , C07D401/04
CPC分类号： C07D487/04 , C07D207/38 , C07D401/04 , C07D401/10 , C07D403/04 , C07D405/14 , C07D409/10 , C07D409/14 , C07D413/10 , C07D413/14 , C07D417/04
摘要： The present invention provides a novel P2X3 and/or P2X2/3 receptor antagonist.A compound represented by the formula (I): wherein Z1 is optionally protected hydroxy, etc.; Z2 is —C(═O)—, etc.; Z3a and Z3b are taken together ═O or ═S; t is an integer of 0 to 4; R4a and R4b are each independently, hydrogen or substituted or unsubstituted lower alkyl, etc.; m and n are each independently an integer of 0 to 2; k is an integer of 0 or 1; Ring A is an aromatic carbocyclic ring or a heterocyclic ring, etc.; B is aromatic carbocyclic ring-diyl or heterocyclic ring-diyl, etc.; R1a and R1b are each independently halogen, hydroxy, substituted or unsubstituted lower alkyl, etc.; R2 is substituted or unsubstituted alkyl, etc.; R3 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, etc.; or its pharmaceutically acceptable salt, or a solvate thereof is provided.
摘要翻译：本发明提供了一种新型的P2X3和/或P2X2 / 3受体拮抗剂。由式（I）表示的化合物：其中Z 1任选被保护的羟基等; Z2是-C（= O） - 等; Z3a和Z3b在一起= O或= S; t为0〜4的整数; R4a和R4b各自独立地为氢或取代或未取代的低级烷基等; m和n各自独立地为0〜2的整数。 k是0或1的整数; 环A是芳族碳环或杂环等; B是芳族碳环环 - 二基或杂环环二基等; R1a和R1b各自独立地为卤素，羟基，取代或未取代的低级烷基等; R2是取代或未取代的烷基等; R3是取代或未取代的烷基，取代或未取代的芳基或取代或未取代的杂环基等; 或其药学上可接受的盐或其溶剂合物。

8. 发明申请

US20100099676A1 SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 审中-公开
标题翻译：选择性抑制MMP-13的SULFONYLUREA衍生物
公开(公告)号：US20100099676A1
公开(公告)日：2010-04-22
申请号：US12447743
申请日：2007-10-31
申请人： Takeshi Endoh , Yasuhiko Fujii , Eiichi Kojima , Genta Tadano , Naoko Yamaguchi , Yo Adachi , Sachie Tagashira , Yuki Tachibana , Naohiro Onodera
发明人： Takeshi Endoh , Yasuhiko Fujii , Eiichi Kojima , Genta Tadano , Naoko Yamaguchi , Yo Adachi , Sachie Tagashira , Yuki Tachibana , Naohiro Onodera
IPC分类号： A61K31/5377 , C07D417/10 , A61K31/497 , C07D413/14 , C07D401/02 , C07D413/02 , A61K31/4965 , C07D241/04
CPC分类号： C07D209/86 , C07D211/96 , C07D213/81 , C07D215/20 , C07D241/04 , C07D243/08 , C07D263/32 , C07D277/28 , C07D295/22 , C07D295/26 , C07D307/81 , C07D307/91
摘要： A compound represented by the general formula (I): wherein R1 is wherein R26 and R28 are each independently lower alkyloxy and the like; n1 is an integer of 0 to 3; Z is a optionally substituted C1-C5 alkynylene which may be interrupted with a substituent selected from Substituent group a and the like; A is a group represented by the formula: wherein R6 and R7 are each independently lower alkyl and the like; m and n are each independently 0, 1, or 2; R2 is a hydrogen atom and the like; R3 is optionally substituted lower alkyl and the like; R4 is a hydrogen atom; or R3 and R4 may be taken together with an adjacent carbon atom to from a ring; R5 is hydroxyl and the like, or an optically active isomer, a pharmaceutically acceptable salt or a solvate thereof.
摘要翻译：由通式（I）表示的化合物：其中R 1是其中R 26和R 28各自独立地为低级烷氧基等; n1为0〜3的整数， Z是可以被选自取代基组a等的取代基中断的任选取代的C 1 -C 5亚炔基; A是由下式表示的基团：其中R6和R7各自独立地为低级烷基等; m和n各自独立地为0,1或2; R2是氢原子等; R3是任选取代的低级烷基等; R4是氢原子; 或者R 3和R 4可以与相邻的碳原子一起与环一起取代; R5是羟基等，或光学活性异构体，其药学上可接受的盐或溶剂化物。

9. 发明申请

US20070210804A1 Load abnormality detecting system and method 失效
标题翻译：负载异常检测系统及方法
公开(公告)号：US20070210804A1
公开(公告)日：2007-09-13
申请号：US11714448
申请日：2007-03-06
申请人： Takeshi Endoh
发明人： Takeshi Endoh
IPC分类号： G01R31/08
CPC分类号： G01R31/025
摘要： A load abnormality detecting system and method for detecting the burnout and short circuit of a load are provided. A voltage generator (10) generates a specified voltage Vs in accordance with a load current IL. A judging device (4) compares a signal corresponding to this voltage (Vs) with a specified reference value (T1, T2) to judge whether a load (2) has any abnormality. A selector (6) causes the burnout reference value (T1) to be inputted to the judging device (4) and controls the voltage generator (10) to use a first resistance value when checking the burnout of the load (2) while causing the short-circuit reference value (T2) to be inputted to the judging device (4) and controlling the voltage generator (10) to use a second resistance value when checking the short circuit of the load (2).
摘要翻译：提供一种用于检测负载的烧坏和短路的负载异常检测系统和方法。电压发生器（10）根据负载电流IL产生规定的电压Vs。判断装置（4）将与该电压（Vs）对应的信号与规定的基准值（T 1，T 2）进行比较，判断负载（2）是否有异常。选择器（6）使得烧断参考值（T 1）被输入到判断装置（4），并且当检查负载（2）的烧坏时，控制电压发生器（10）使用第一电阻值，同时引起输入到判断装置（4）的短路参考值（T 2），并且在检查负载（2）的短路时控制电压发生器（10）使用第二电阻值。

10. 发明授权

US07525318B2 Load abnormality detecting system and method 失效
标题翻译：负载异常检测系统及方法
公开(公告)号：US07525318B2
公开(公告)日：2009-04-28
申请号：US11714448
申请日：2007-03-06
申请人： Takeshi Endoh
发明人： Takeshi Endoh
IPC分类号： G01R31/08
CPC分类号： G01R31/025
摘要： A load abnormality detecting system and method for detecting the burnout and short circuit of a load are provided. A voltage generator (10) generates a specified voltage Vs in accordance with a load current IL. A judging device (4) compares a signal corresponding to this voltage (Vs) with a specified reference value (T1, T2) to judge whether a load (2) has any abnormality. A selector (6) causes the burnout reference value (T1) to be inputted to the judging device (4) and controls the voltage generator (10) to use a first resistance value when checking the burnout of the load (2) while causing the short-circuit reference value (T2) to be inputted to the judging device (4) and controlling the voltage generator (10) to use a second resistance value when checking the short circuit of the load (2).
摘要翻译：提供一种用于检测负载的烧坏和短路的负载异常检测系统和方法。电压发生器（10）根据负载电流IL产生规定的电压Vs。判断装置（4）将与该电压（Vs）对应的信号与规定的基准值（T1，T2）进行比较，判断负载（2）是否有异常。选择器（6）使得将烧坏参考值（T1）输入到判断装置（4），并且当检查负载（2）的烧坏同时使电压发生器（10）使用第一电阻值，同时使输入到判断装置（4）的短路基准值（T2），并且在检查负载（2）的短路时，控制电压发生器（10）使用第二电阻值。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式